135094-10-9Relevant academic research and scientific papers
FUSED TRICYCLIC SILYL COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
Paragraph 0250, (2015/12/08)
no abstract published
SILYL-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
Page/Page column 62; 63, (2013/03/28)
The present invention relates to novel Silyl-Containing Heterocyclic Compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, wherein A, B, C, D and R2 are as defined herein. The present invention also relates to compositions comprising at least one Silyl-Containing Heterocyclic Compound, and methods of using the Silyl-Containing Heterocyclic Compounds for treating or preventing HCV infection in a patient.
TETRACYCLIC HETEROCYCLE COMPOUNDS FOR TREATING HEPATITIS C VIRAL INFECTION
-
Page/Page column 70-71, (2012/04/17)
Tetracyclic heterocycle compounds of formula (I) and pharmaceutically acceptable salts thereof are provided, wherein A, A', G, R1, R15, U, V, V', W, W, X, X', Y and Y' are as defined in the invention. The pharmaceutical compositions comprising these compounds and the use of the compounds for treating hepatitis C virus (HCV) infection are also provided.
TETRACYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
Page/Page column 77-78, (2012/04/17)
The present invention relates to novel Tetracyclic Indole Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprisingat least one Tetracyclic Indole Derivative, and methods of using the Tetracyclic Indole Derivatives for treating or preventing HCV infection in a patient.
FUSED TETRACYCLE DERIVATIVES AND METHODS OF USE THEREOF FOR THE TREATMENT OF VIRAL DISEASES
-
Page/Page column 77, (2012/05/04)
The present invention relates to novel Fused Tetracycle Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', B, G, R1, U, V, W, W', X, X', Y and Y' are as defined herein. The present invention also relates to compositions comprising at least one Fused Tetracycle Derivative, and methods of using the Fused Tetracycle Derivatives for treating or preventing HCV infection in a patient.
FUSED TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR TREATMENT OF VIRAL DISEASES
-
Example 6, (2012/04/17)
The present invention discloses novel Fused Tetracyclic Heterocycle Compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein A, A', G, R1, R15, U, V, V', W, W', X, X', Y and Y' are as defined herein. The present invention also discloses compositions comprising at least one Fused Tetracyclic Heterocycle Compound, and methods of using the Fused Tetracyclic Heterocycle Compounds for treating or preventing HCV infection in a patient.
Novel inhibitors of hepatitis C NS3-NS4A serine protease derived from 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid
Venkatraman, Srikanth,Njoroge, F. George,Wu, Wanli,Girijavallabhan, Viyyoor,Prongay, Andrew J.,Butkiewicz, Nancy,Pichardo, John
, p. 1628 - 1632 (2007/10/03)
Prolonged hepatitis C infection is the leading cause for cirrhosis of the liver and hepatocellular carcinoma. The etiological agent HCV virus codes a single polyprotein of ～3000 amino acids that is processed with the help of a serine protease NS3A to prod
Aza-Diels - Alder reaction of methyl 2-[(R)-1-phenylethyl]iminoethanoate with cyclopentadiene using practical and environmentally friendly biphasic solvent system
Hashimoto, Norio,Yasuda, Hironobu,Hayashi, Masaru,Tanabe, Yoo
, p. 105 - 109 (2012/12/24)
Aza-Diels - Alder reaction between 2-[(R)-1-phenylethyl]imino-ethanoate (1) and cyclopentadiene using the biphasic solvent system (TMSCl-CH 3OH/toluene) gave (1S,3S,4R)-2-[(R)-1-phenylethyl]-2-aza-bicyclo[2.2. 1]hept-5-ene-3-carboxylates (3a) i
Synthesis and evaluation of chiral bicyclic proline FKBP12 ligands
Limburg, David C.,Thomas IV, Bert E.,Li, Jia-He,Fuller, Mike,Spicer, Dawn,Chen, Yi,Guo, Hongzhi,Steiner, Joseph P.,Hamilton, Gregory S.,Wu, Yong-Qian
, p. 3867 - 3870 (2007/10/03)
As part of our ongoing program to explore novel structural classes of FKBP12 ligands, we herein wish to report a new class of FKBP12 ligands containing chiral bicyclic proline analogues. Details of the synthetic routes, together with preliminary biologica
Bridged bicyclic vasopressin receptor antagonists with V2-selective or dual V1a/V2 activity
Dyatkin, Alexey B.,Hoekstra, William J.,Hlasta, Dennis J.,Andrade-Gordon, Patricia,De Garavilla, Lawrence,Demarest, Keith T.,Gunnet, Joseph W.,Hageman, William,Look, Richard,Maryanoff, Bruce E.
, p. 3081 - 3084 (2007/10/03)
The synthesis and biological testing of a novel series of nonpeptide vasopressin receptor antagonists, containing a bridged bicyclic nucleus, are reported. Variation of substituents (R1-R3) in general formula 3, and the configuration
